EUVIMEDEUVIMED entdecken
Open Access

Sociodemographic trends in prostate cancer: insights from the All of Us Research Program

Dhruv G Pillai, Vivian A Guedes iD, Nicholas G Micheletti, Jessica D Kindrick, Benjamin C Brim iD, Hyoyoung Choo-Wosoba iD, Cindy H Chau iD, William D Figg iD

JNCI Cancer Spectrum · 2026

DOI: 10.1093/jncics/pkag070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Dhruv G Pillai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heal…. Hauptthemen laut MEDLINE: Healthcare Disparities, Prostatic Neoplasms. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Center for Cancer Research, National Cancer Institute, National Institutes of Health Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer disproportionately affects vulnerable populations. The All of Us Research Program (AoURP) is a database that aims to encapsulate the diversity of the United States. To explore the utility of this dataset in assessing prostate cancer disparities, we investigated whether treatment usage, disease progression, and genomic research participation vary across sociodemographic factors among AoURP participants with prostate cancer.

Methods

We identified AoURP participants with prostate cancer. Genomic research participation in AoURP, treatment usage, time-to-treatment, and time-to-metastasis were assessed by demographics and distance from a National Cancer Institute–designated comprehensive cancer center. Multivariable logistic regression and Cox proportional hazards regression were performed to evaluate treatment usage and time-to-treatment and time-to-metastasis, respectively.

Results

We observed lower genomic data availability in Black vs White patients (P < .001). In multivariable analyses, patients residing more than 80 miles from an NCI-designated comprehensive cancer center were less likely to receive androgen receptor pathway inhibitors (odds ratio [OR] = 0.30, 95% CI = 0.14 to 0.66; P = .002) and bone targeting agents (OR = 0.46, 95% CI = 0.30 to 0.70; P < .001) but more likely to undergo prostatectomy (OR = 1.97, 95% CI = 1.43 to 2.71; P < .001) than those residing less than 40 miles away. These patients also initiated treatment faster (hazard ratio [HR] = 1.54, 95% CI = 1.27 to 1.87; P < .001) and developed metastasis slower (HR = 0.58, 95% CI = 0.40 to 0.86; P = .006). Black patients were less likely to receive radiation (OR = 0.45, 95% CI = 0.23 to 0.88; P = .020), prostatectomy (OR = 0.65, 95% CI = 0.44 to 0.96; P = .028), and bone targeting agents (OR = 0.65, 95% CI = 0.45 to 0.93; P = .018) than White patients.

Conclusions

Prostate cancer treatment usage, disease progression, and genomic research participation varied between demographic populations. As AoURP matures, additional studies may leverage future data releases to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Healthcare DisparitiesProstatic NeoplasmsAgedHumansMaleMiddle AgedAndrogen AntagonistsBlack or African AmericanDatabases, FactualDisease ProgressionLogistic ModelsNational Cancer Institute (U.S.)Proportional Hazards ModelsProstatectomyTime FactorsUnited StatesWhite

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

ORCID-Profile: Vivian A Guedes, Benjamin C Brim, Hyoyoung Choo-Wosoba, Cindy H Chau, William D Figg

Förderung

  • Intramural NIH HHS
  • Center for Cancer Research, National Cancer Institute, National Institutes of Health Intramural Research

Zitieren

APA

Pillai, D. G., Guedes, V. A., Micheletti, N. G., Kindrick, J. D., Brim, B. C., Choo-Wosoba, H., Chau, C. H., & Figg, W. D. (2026). Sociodemographic trends in prostate cancer: insights from the All of Us Research Program. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag070

Vancouver

Pillai DG, Guedes VA, Micheletti NG, Kindrick JD, Brim BC, Choo-Wosoba H, et al. Sociodemographic trends in prostate cancer: insights from the All of Us Research Program. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag070

BibTeX
@article{Pillai2026,
  author = {Pillai, Dhruv G and Guedes, Vivian A and Micheletti, Nicholas G and Kindrick, Jessica D and Brim, Benjamin C and Choo-Wosoba, Hyoyoung and Chau, Cindy H and Figg, William D},
  title = {Sociodemographic trends in prostate cancer: insights from the All of Us Research Program},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  doi = {10.1093/jncics/pkag070}
}
Kostenlos starten →